Certain Shares of Xvivo Perfusion AB are subject to a Lock-Up Agreement Ending on 27-APR-2022.
Details:
The Company has agreed to a lock-up undertaking, with customary exceptions, on future share issuances for a period of 180 calendar days after the settlement date of the Directed Issue. In addition, the members of the Board of Directors and certain members of the senior management of the Company, have agreed to not sell any shares in XVIVO for a period of 180 calendar days after the settlement date of the Directed Issue, subject to customary exceptions.